ALIMERA SCIENCES SECURES $31.8 MILLION IN SERIES B FINANCING

Alimera Sciences Inc., an ophthalmic pharmaceutical company, announced today that it has completed Series B financing, securing $31.8 million in venture capital. Premier venture firm Venrock Associates led the new round, and all four original Series A firms continued their investment. The additional resources will be used to further develop Alimera Sciences' retinal portfolio, including Medidur(TM), the company's Phase III-stage treatment for diabetic macular edema (DME).
American Venture Magazine